Biohit Oyj (HEL:BIOBV)

Market Cap	51.06M +5.8%
Revenue (ttm)	14.28M +2.2%
Net Income	2.27M +37.4%
EPS	0.15 +36.9%
Shares Out	15.20M
PE Ratio	22.49
Forward PE	22.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,060
Average Volume	10,116
Open	3.380
Previous Close	3.360
Day's Range	3.310 - 3.380
52-Week Range	2.351 - 3.780
Beta	0.63
RSI	47.47
Earnings Date	Feb 11, 2026

About Biohit Oyj

Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company’s diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist clinicians and general practitioner; BIOHIT Active B12, a test for measuring the concentration of total vitamin-B12 in the serum; BIOHIT Total 25OH Vit...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1988
• Employees: 49
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: BIOBV

Financial Performance

In 2024, Biohit Oyj's revenue was 14.28 million, an increase of 9.23% compared to the previous year's 13.08 million. Earnings were 2.57 million, an increase of 38.74%.